Correction: MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1
Venturutti, L., Russo, R. I. Cordo, Rivas, M. A., Mercogliano, M. F., Izzo, F., Oakley, R. H., Pereyra, M. G., De Martino, M., Proietti, C. J., Yankilevich, P., Roa, J. C., Guzmán, P., Cortese, E., Allemand, D. H., Huang, T. H., Charreau, E. H., Cidlowski, J. A., Schillaci, R., Elizalde, P. V.
Published in Oncogene (01.12.2023)
Published in Oncogene (01.12.2023)
Get full text
Journal Article
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1
Venturutti, L, Cordo Russo, R I, Rivas, M A, Mercogliano, M F, Izzo, F, Oakley, R H, Pereyra, M G, De Martino, M, Proietti, C J, Yankilevich, P, Roa, J C, Guzmán, P, Cortese, E, Allemand, D H, Huang, T H, Charreau, E H, Cidlowski, J A, Schillaci, R, Elizalde, P V
Published in Oncogene (01.12.2016)
Published in Oncogene (01.12.2016)
Get full text
Journal Article